Rheumatology in Geriatrics

  • Fred G. Kantrowitz
  • George Munoz
  • Neal Roberts
  • Sam Schatten
  • Steve Stern
Part of the Contemporary Geriatric Medicine book series (COGM, volume 2)


Normal aging is associated with changes in both arms of the immune system, namely, cell-mediated immunity and humoral immunity.1 In the former, after appropriate activation, T lymphocytes, whether helper T cells (Th), suppressor T cells (Ts), or cytotoxic T cells (TCTL), proliferate and perform their various functions; in the latter, B lymphocytes, after appropriate activation, eventually synthesize and secrete antibodies.2 The two best studied age-related changes are the diminished T-cell-dependent immune responses to foreign antigens and the increase in the incidence of autoantibodies.


Rheumatoid Arthritis Systemic Lupus Erythematosus Articular Cartilage Systemic Lupus Erythematosus Patient Giant Cell Arteritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weksler, M. E., 1981, The senescence of the immune system, Hosp. Prac. 16 (10): 53–64.Google Scholar
  2. 2.
    Paul, W. E., The immune system: An Introduction in: Fundamental Immunology (W. E. Paul, ed.), Raven Press, New York, pp. 3–22.Google Scholar
  3. 3.
    Weksler, M. E., 1980, The immune system and the aging process in man, Proc. Soc. Exp. Biol. Med. 165: 200–205.PubMedGoogle Scholar
  4. 4.
    Wekster, M. E. and Hutteroth, T. H., 1974, Impaired lymphocyte function in aged humans, J. Clin. Invest. 53: 99–104.Google Scholar
  5. 5.
    Goto, M., Horiuchi, Y., Okumura, K., Tada, T., Kawata, M., and Ohmori, K., 1979, Immunological abnormalities of aging: An analysis of T lymphocyte subpopulations of Werner’s syndrome, J. Clin. Invest. 64: 695–699.PubMedGoogle Scholar
  6. 6.
    Wallace, D. H. Bluestone, R., and Klinenberg, J. R., 1982, The biology of aging and the immune system. Bull. Rheum. Dis. 32: 13–19.PubMedGoogle Scholar
  7. 7.
    Gottesman, S. R. S., Walford, R. L., and Thorbecke, G. J., 1984, Prolifeartive and cytotoxic immune functions in aging mice. II. Decreased generation of specific suppressor cells in alloreactive cultures, J. Immunol. 133: 1782–1787.PubMedGoogle Scholar
  8. 8.
    Antel, J. P., Oger, J. J.-F., Dropcho, E., Richman, D. P., Kuo, H. H., and Arnason, B. G. W., 1980, Reduced T-lymphocyte cell reactivity as a function of human aging, Cell. Immunol. 54: 184–192.Google Scholar
  9. 9.
    Roberts-Thomson, I. C., Whittingham, S., Youngchaiyud, U., and Mackay, I. R., 1974, Ageing, immune response, and mortality, Lancet 2: 368–370.PubMedGoogle Scholar
  10. 10.
    Waldorf, D. S., Willkens, R. F., and Decker, J. L., 1968, Impaired delayed hyper-sensitivity in an aging population, JAMA 203: 831–834.PubMedGoogle Scholar
  11. 11.
    Hallgren, H. M., Buckley, III, C. E., Gilbertsen, V. A., and Yunis, E. J., 1973, Lymphocyte phytohemagglutinin responsiveness, immunoglobulins and autoanti-bodies in aging humans, J. Immunol 111: 1101–1107.Google Scholar
  12. 12.
    Staiano-Coico, L., Darzynkiewicz, Z., Melamed, M. R., and Weksler, M. E., 1984, Immunological studies of aging. IX. Impaired proliferation of T lymphocytes detected in elderly humans by flow cytometry, J. Immunol. 132: 1788–1792.PubMedGoogle Scholar
  13. 13.
    Somers, H. and Kuhns, W. J., 1972, Blood group antibodies in old age, Proc. Soc. Exp. Biol. Med. 141: 1104–1107.PubMedGoogle Scholar
  14. 14.
    Goto, M., Tanimoto, K, Aotsuka, S., Okawa, M., and Yokohari, R., 1982, Age-related changes in auto- and natural antibody in the Werner syndrome, Am. J. Med. 72: 607–614.PubMedGoogle Scholar
  15. 15.
    Klajman, A. Kafri, B., Shohat, T., Drucker, I., Moalem, T., and Jaretzky, A., 1983, The prevalence of antibodies to histones induced by procainamide in old people, in cancer patients, and in rheumatoid-like disease, Clin. Immunol. Immunopathol. 27: 1–8.Google Scholar
  16. 16.
    Duchateau, J., Delepesse, G., Vrijens, R., and Collet, H., 1981, Beneficial effects or oral zinc supplementation on the immune response of old people, Am. J. Med. 70: 1001–1004.PubMedGoogle Scholar
  17. 17.
    Miller, A, Green, M., and Robinson, D., 1983, Simple rate for calculating normal erythrocyte sedimentation role, Br. Med. J. 286: 266.Google Scholar
  18. 18.
    Waller, P. C. and Ramsay, L. E., 1984, (letter) Normal erythrocyte sedimentation in the elderly, Br. Med. J. 289: 1146–1147.Google Scholar
  19. 19.
    Kusher, I., 1981, The acute phase reactants and the erythrocyte sedimentation rate, in: Textbook of Rheumatology ( W. N. Kelly, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, eds.), W. B. Saunders Company, Philadelphia, pp. 669–676.Google Scholar
  20. 20.
    Bottiger, L. E. and Svedberg, C. A., 1967, The normal erythrocyte sedimentation rate and age, Br. Med. J. 2: 85–87.PubMedGoogle Scholar
  21. 21.
    Hayes, G. S. and Stinson, I. N., 1976, Erythrocyte sedimentation rate and age, Arch. Ophthalmol. 94: 939–940.Google Scholar
  22. 22.
    Zacharski, L. R. and Kyle, R. A., 1967, Significance of extreme elevations of erythrocyte sedimentation rates, JAMA 202: 264–266.PubMedGoogle Scholar
  23. 23.
    Cammarata, P. G., Rodnan, G. P., and Fennell, R. H., 1967, Serum anti-gammaglobulin and anti-nuclear factors in the aged, JAMA 199: 455–458.PubMedGoogle Scholar
  24. 24.
    Mikkelson, W. M., Dodge, H. J., Duff, I. V., and Kato, H., 1967, Estimates of the prevalence of rheumatic disease in the population of Tecumseh, Michigan 1950–50, J. Chronic Dis. 20: 351–369.Google Scholar
  25. 25.
    Litwen, S. D. and Singer, J. M., 1965, Studies of the incidence and significance of anti-gammaglobulin factors in aging, Arthritis Rheum. 8: 538–550.Google Scholar
  26. 26.
    Giansiracusa, D. F. and Kantrowitz, F. G., 1982, Pseudogout: Calcium pyro-phosphate dihydrate deposition disease, Rheumatic and Metabolic Bone Diseases in the Elderly, The Collamore Press, Lexington, Massachusetts, pp. 45–54.Google Scholar
  27. 27.
    Fernandez-Madrid, F. and Mattioli, M., 1976, Anti-nuclear antibodies (ANA): Immunologic and clinical significance, Sem. Arth. Rheum. 6: 83–124.Google Scholar
  28. 28.
    Friou, G. J. and Quismorio, F. P., 1975, The LE cell factor and antinuclear anti-bodies, in: Laboratory Diagnostic Procedures in the Rheumatic Diseases, 2nd ed. ( A. S. Cohen, ed.), Little, Brown and Company, Boston, pp. 159–206.Google Scholar
  29. 29.
    Notman, D. D., Kurata, N., and Tan, E. M., 1975, Profiles of antinuclear antibodies in systemic rheumatic disease, Ann. Intern. Med. 83: 464–469.PubMedGoogle Scholar
  30. 30.
    Svec, K. H. and Viet, B. C., 1967, Age-related anti-nuclear factors: Immunologic characteristics and associated clinical aspects, Arthritis Rheum. 10: 509–516.PubMedGoogle Scholar
  31. 31.
    Alarcon-Segovia, D. and Fishbein, E., 1975, Patterns of anti-nuclear antibodies and lupus activating drugs, J. Rheumatol. 2: 167–171.PubMedGoogle Scholar
  32. 32.
    Davis, J. S., 1981, Anti-nuclear antiboides (ANA), in: Textbook of Rheumatology, ( W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, eds.) W. B. Saunders Company, Philadelphia, pp. 694–697.Google Scholar
  33. 33.
    Chubick, A., Sontheimer, R. D., Gilliam, J. N., and Ziff, M., 1978, An appraisal of tests for native DNA antibodies in connective tissue disease, Ann. Intern. Med. 89: 186–192.PubMedGoogle Scholar
  34. 34.
    Lloyd, W. and Schur, P. H., 1981, Immune complexes, complement, and anti-DNA in exacerbtaions of systemic lupus erythematosus (SLE), Medicine 60: 208–217.PubMedGoogle Scholar
  35. 35.
    Richardson, B. and Epstein, W. V., 1981, Utility of the flourescent anti-nuclear antibody test in a single patient, Ann. Intern Med. 95: 333–338.PubMedGoogle Scholar
  36. 36.
    Shiel W. C. and Prete, P. E., 1984, Pleuropulmonary manifestations of Rheumatoid Arthritis, Sem. Arth. Rheum. 13: 235–243.Google Scholar
  37. 37.
    Harris, E. D., Jr., 1981, Pathogenesis of rheumatoid arthritis, in: Textbook of Rheumatology (W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, eds.) W. B. Saunders Company, Philadelphia, pp. 896–927.Google Scholar
  38. 38.
    Statsny, P., 1977, Immunogenetic factors in rheumatoid arthritis, Clin. Rheum. Dis. 3: 315–332.Google Scholar
  39. 39.
    Statsny, P., 1978, Association of the B-cell alloantigen DR W4 with rheumatoid arthritis, N. Engl. J. Med. 298: 869.Google Scholar
  40. 40.
    Young, A., et al., 1984, Association of HLA-DR4/DW4 and DR2/DW2 with radiologic changes in a prospective study of patients with rheumatoid arthritis, Arthritis Rheum. 27: 20 - 25.PubMedGoogle Scholar
  41. 41.
    Griffin, A. J., Wooley, P., Panay, G. S., and Batchelor, J. R., 1984, HLA DR antigens and disease expression in rheumatoid arthritis, Ann. Rheum. Dis. 43: 218–221.PubMedGoogle Scholar
  42. 42.
    Speerstra, F., Reekers, P., Van, de Pulte, L. B. A., Vendenbroucker, J. P., Raska, J. J. et al., 1983, HLA-DR antigens and proteinuria induced by aurothioglucose and D-pencillamine in patients with rheumatoid arthritis, J. Rheum. 10: 948–953.PubMedGoogle Scholar
  43. 43.
    Coblyn, J. S., Weinblatt, M., Holdsworth, D., et al., 1981, Gold induced thrombocytopenia: A clinical and immunogenetic study of twenty three patients, Ann. Intern. Med. 95: 178–181.PubMedGoogle Scholar
  44. 44.
    Adachi, J., Berger, W. G., et al., 1984, Gold induced thrombobytopenia: Platelet associated Ig and HLA typing in three patients, J. Rheum. 11: 355.PubMedGoogle Scholar
  45. 45.
    Ropes, M. W. Bennett, G. A., Cobb, S. Jocox, R., and Jessar, R. A., 1958, 1958 revision of diagnostic criteria for rheumatoid arthritis, Bull. Rheum. Dis. 9: 175–176.Google Scholar
  46. 46.
    Mikkelson, W. M., Dodge, H. J., Duff, I. C., and Kato, H., 1967. Estimates of the prevalence of rheumatic disease in the population of Tecumseh, Michigan 1950–50, J. Chronic Dis. 20: 351–369.Google Scholar
  47. 47.
    Engel, A. Roberts, J., and Burch, T. A., 1966, Rheumatoid arthritis in adults in the United States 1960–1962, in: Vital and Health Statistics, Series 11, Data from the National Health Survey, Number 17. National Center for Health Statistics, Washington, D.C.Google Scholar
  48. 48.
    Cathcart, E. S. and O’Sullivan, J. B., 1970, Rheumatoid arthritis in a New England town: A prevalence study in Sudbury, Massachusetts, N. Engl. J. Med. 282: 421–424.PubMedGoogle Scholar
  49. 49.
    Lenos, A., Worthington, J. W., O’Fallon, W. M., and Kurland, L. T., 1980, The epidemiology of rheumatoid arthritis in Rochester, Minnesota: A study of incidence, prevalence, and mortality, Am. J. Epidemiol. 111: 87–98.Google Scholar
  50. 50.
    Christian, C. L., 1979, Rheumatoid arthritis, in: Textbook of Medicine ( P. Beeson, W. McDermott, and J. B., Wyngaarden, eds.), W. B. Saunders Company, Philadelphia, pp. 186–187.Google Scholar
  51. 51.
    Moesmann, G., 1968, Subacute rheumatoid arthritis in old age, 1., Acta. Rheum. Scand. 14: 14–23.Google Scholar
  52. 52.
    Erlich, G. E., Katz, W. A., and Cohen, S. H., 1970, Rheumatoid arthritis in the elderly, Geriatrics, 25: 103–113.Google Scholar
  53. 53.
    Brown, J. W. and Sones, D. A., 1967, The onset of rheumatoid arthritis in the aged, J. Am. Genat. Soc. 15: 873–881.Google Scholar
  54. 54.
    Pearson, C. M., Barnett, E. Kroening, R., Mormor, L., Murray, J. F., Peter, J. B., and Salick, A., 1966, Rheumatoid arthritis and its systemic manifestations, Ann. Intern. Med. 65: 1101–1130.Google Scholar
  55. 55.
    Short, C. L., 1968, Rheumatoid arthritis: Types of course and prognisis, Med. Clin. N. Am. 52: 549–557.PubMedGoogle Scholar
  56. 56.
    Lockie, L. M. and Talbot, J. H., 1956, Arthritis in the aged, JAMA 162: 1514–1517.Google Scholar
  57. 57.
    Corrigan, A. B., Robinson, R. G., Terenty, T. R., Dick-Smith, J. B., and Walters, D., 1974, Benign rheumatoic arthritis of the aged, Br. Med. J. 1: 444–445.PubMedGoogle Scholar
  58. 58.
    Deal, C., Goldenberg, D., Meenan, R., Sack, B., Pastan, R., and Cohen, A. S., 1981, Elderly onset rheumatoid arthritis: A comparison with earlier onset, matched for disease duration, Arthritis: Rheum. 24: 599 (abstract).Google Scholar
  59. 59.
    Terkeltraub, R., Esdaile, J. Décary, F. and Tannenbaum, H., 1983, A clinical study of older age rheumatoid arthritis with comparison to a younger onset group, J. Rheum. 10: 418.Google Scholar
  60. 60.
    Jacoby, R. K., Jayson, M. I. V., and Cosh, J. A., 1973, Onset, early stages and prognosis of rheumatoid arthritis: A clinical study of 100 patients with 11-year follow-up, Br. Med. J. 2: 96–100.PubMedGoogle Scholar
  61. 61.
    Terkeltraub, R., Decary, F., and Esdaile, J., 1984, An immunogenetic study of older age onset rheumatoid arthritis, J. Rheum. 11: 147.Google Scholar
  62. 62.
    Ruddy, S., 1981, The management of rheumatoid arthritis, Textbook of Rheumatology (W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, eds.), W. B. Saunders Company, Philadelphia, pp. 1000–1014.Google Scholar
  63. 63.
    Simon, L. S. and Mills, J. A., 1980, Nonsteroidal anti-inflammatory drugs, N. Engl. J. Med. 302:1179–1185 1237–1243.Google Scholar
  64. 64.
    Bunch, T. W. and O’Duffy, J. D., 1980, Disease-modifying drugs for progressive rheumatoid arthritis, Mayo Clin. Proc. 55: 161–179.Google Scholar
  65. 65.
    Skibsted, Als O, Christiansen, C., et al., 1984, Prevalence of decrease bone mass in rheumatoid arthritis. Relation of antiinflammatory treatment, Clin. Rheum. 3: 201–208.Google Scholar
  66. 66.
    Liang, M. H., Partridge, A. J., Larson, M. G., et al., 1984, Evaluation of comprehensive rehabilitation services for elderly homebound patients with rheumatoid arthritis and orthopedic disability, Arth. Rheum. 27: 258–266.Google Scholar
  67. 67.
    Harris, E. D. Jr., Emkey, R. D., Nichols, J. E., and Newberg, A., 1983, Low dose prednisnone therapy in rheumatoid arthritis: A double blind study, J. Rheum 10: 713.PubMedGoogle Scholar
  68. 68.
    Dykman, Thomas R., Haralson, Kathleen M., Gluck, Oscar S., et al., 1984, Effect of oral 1,25-Dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases, Arthritis Rheum, 27: 1336–1343.PubMedGoogle Scholar
  69. 69.
    Dubois, E. L., 1974, Lupus Erythematosus: A Review of the Current Status of Disease and Systemic Lupus Erythematosus, 2nd ed. University of Southern California Press, Los Angeles.Google Scholar
  70. 70.
    Fries, J. F. and Holman, H. R., 1975, Systemic Lupus Erythematosus, W. B. Saunders Company, Philadelphia.Google Scholar
  71. 71.
    Ropes, M. W., 1976, Systemic Lupus Erythematosus, Harvard University Press, Cambridgee, Massachusetts.Google Scholar
  72. 72.
    Rothfield, N., 1981, Clinical features of systemic lupus erythematosus, in: Textbook of Rheumatology, ( W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, eds.) W. B. Saunders Company, Philadelphia, pp. 1106–1132.Google Scholar
  73. 73.
    Schur, P., 1983, The Clinical Management of Systemic Lupus Erythematosus, Grune & Stratton, Inc., New York.Google Scholar
  74. 74.
    Rothfield, N. F., 1979, Lupus erythematosus, in: Dermatology in General Medicine, 2nd ed. ( T. Fitzpatrick, ed.), McGraw-Hill Book Company, New York, pp. 1273–1298.Google Scholar
  75. 75.
    Matthay, R. A., Schwarz, M. I., Petty, T. L., Stanford, R. E., Gupta, R. C., Sahn, S. A., and Steigerwald, T. C., 1974, Pulmonary manifestations of systemic lupus erythematosus: Review of 12 cases of acute lupus pneumonitis, Medicine, 54: 397–409.Google Scholar
  76. 76.
    Labowitz, B. and Schumacher, H. R., 1971, Articular manifestations of systemic lupus erythematosus, Ann. Intern. Med. 74: 911–921.PubMedGoogle Scholar
  77. 77.
    Zizic, T. M., Hungerford, D. S., and Stevens, M. D., 1980, Ischemic bone necrosis in systemic lupus erythematosus, Parts I & II, Medicine 59: 134–147.PubMedGoogle Scholar
  78. 78.
    Budman, D. R. and Sternberg, A. D., 1977, Hematologic aspects of systemic lupus erythematosus, Ann. Intern. Med. 86: 220–229.PubMedGoogle Scholar
  79. 79.
    Austin, H. A., III, Muenz, L. R., Joyce, K. M., Antonovych, T. A., Kullick, M. E., Klippel, J. H., Decker, J. L. and Balow, J. E., 1983, Prognostic factors in lupus nephritis, Am. J. Med. 75: 383–391.Google Scholar
  80. 80.
    Baldwin, D. S., Gluck, M. C., Lowenstein, J. and Gallo, G. R., 1977, Lupus nephritis, Am. J. Med. 62: 12–30.PubMedGoogle Scholar
  81. 81.
    Fries, J. F., Porta, J., and Liang, M. H., 1978, Marginal benefits of renal biopsy in systemic lupus erythematosus, Arch. Intern. Med. 138: 1386–1389.Google Scholar
  82. 82.
    Ginzier, E. M., Bollet, A. J., and Friedman, R. A., 1980, The Natural history and response to therapy of lupus nephritis, Ann. Rev. Med. 31: 46–487.Google Scholar
  83. 83.
    Hoffman, B. I. and Katz, W. A., 1980, The gastrointestinal manifestation of systemic lupus erythematosus, Semin. Arth. Rheum. 9: 237–247.Google Scholar
  84. 84.
    Bluestein, H. G., Williams, G. W., and Steinberg, A. D., 1981, Cerebrospinal fluid antibodies to neuronal cells, Am. J. Med. 70: 240–246.PubMedGoogle Scholar
  85. 85.
    Feinglass, E. J., Arnett, F. C., Dorsch, C. A., Zizic, T. M., and Stevens, M. B., 1976, Neuropsychiatric manifestations of systemic lupus erythematosus: Diagnosis, clinical spectrum and relationship to other features of the disease, Medicine 55: 323–339.PubMedGoogle Scholar
  86. 86.
    Zvaifler, N. J. and Bluestein, H. G., 1982, The pathogenesis of central nervous system manifestation of systemic lupus erythematosus, Arthritis Rheum. 25: 862–866.PubMedGoogle Scholar
  87. 87.
    Steinberg, A. D., et al., 1984, Systemic lupus erythematosus: Insights from animal models, Ann. Intern. Med. 100: 714–727.PubMedGoogle Scholar
  88. 88.
    Reinertsen, J. L., Klippel, J. II., Steinberg, A. D., Decker, J. L., and Mann, D. L., 1978, B-lymphocyte alloantigens associated with systemic lupus erythematosus, N. Engl. J. Med. 299: 515–518.PubMedGoogle Scholar
  89. 89.
    Tan, E. M. Cohen, A. S., Fries, J. F., Masi, A. T., McShane, D. J., Rothfield, F., Schaller, J. G., Talol, N., and Winchester, R. J., 1982, Revised criteria for the clarification of systemic lupus erythematosus, Arthritis Rheum. 25: 1271–1277.Google Scholar
  90. 90.
    Lloyd, W. and Schur, P. H., 1981, Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE), Medicine 60: 208–217.PubMedGoogle Scholar
  91. 91.
    Richardson, B. and Epstein, W. V., 1981, Utility of the flourescent anti-nuclear antibody test in a single patient, Ann. Intern. Med. 95: 333–338.PubMedGoogle Scholar
  92. 92.
    Synkowski, D. R., Mogavero, H. S. and Provost, T. T., 1980, Lupus erythematosus: Laboratory testing and clinical subsets in the evaluation of patients, Med. Chn. North Am. 64: 921–940.Google Scholar
  93. 93.
    Reichlin, M., 1982, Clinical and immunological significance of antibodies to Ro and La in systemic lupus erythematosus, Arthritis Rheum. 25: 767–769.PubMedGoogle Scholar
  94. 94.
    Foad, B. S. I., Sheon, R. P., and Kirsner, A. B., 1972, Systemic lupus erythematosus in the elderly, Arch. Int. Med. 130: 743–746.Google Scholar
  95. 95.
    Dimant, J., Ginzier, E. M., Schlesinger, M., Diamond, H. S., and Kaplan, D., 1979, Systemic lupus erythematosus in the older age group: Computer analysis, J. Amer. Geriat. Soc. 27: 58–61.PubMedGoogle Scholar
  96. 96.
    Baker, S. B., Rovera, J. R., Campion, E. W., and Mills, J. A., 1979, Late onset systemic lupus erythematosus, Am. J. Med. 66: 727–732.PubMedGoogle Scholar
  97. 97.
    Wilson, H. A., Winfield, J. B., Hamilton, M. E., Spyker, D. A., Brunner, C. M., and Davis, J. S., 1979, Serologic studies in late onset systemic lupus erythematosus, Arthritis Rheum. 22: 674 (abstract).Google Scholar
  98. 98.
    Ballou, S. P., Khan, M. A., and Kirshner, I., 1982, Clinical features of systemic lupus erythematosus: Differences related to race and age of onset, Arthritis Rheum. 25: 55–60.PubMedGoogle Scholar
  99. 99.
    Siegel, M. and Lee, S. L., 1973, The epidemiology of systemic lupus erythematosus, Sem. Arth. Rheum. 3: 1–54.Google Scholar
  100. 100.
    Maddock, R. K., 1965, Incidence of systemic lupus erythematosus by age and sex, JAMA 191: 137–138.PubMedGoogle Scholar
  101. 101.
    Urowitz, M. B., Steven, M. D., and Shulman, L. E., 1967, The influence of age on the clinical pattern of systemic lupus erythematosus, Arthritis Rheum. 101: 319–320 (abstract).Google Scholar
  102. 102.
    Catoggio. L. J., Skinner, R. R., Smith, G., and Maddison, P. J., 1984, systemic lupus erythematosus in the elderly: Clinical and serologic characteristic, J. Rheum. 11: 175–181.Google Scholar
  103. 103.
    Boey, M. L., Colaco, C. B., Gharavi, A. E., Elkon, K. B., Lorzoi, S., and Hughes, G. R. V., 1983, Thrombosis in SLE: striking association with the presence of circulating lupus anticoagulant, Br. Med. J. 287: 1021–1023.Google Scholar
  104. 104.
    Hughes, G. R. V., 1983, The lupus anticoagulant, Br. Med. J. 287: 1088–1089.Google Scholar
  105. 105.
    Seaman, W. E. and Plotz, P. H., 1976, Effect of aspirin on liver tests in patients with RA or SLE and in normal volunteers, Arthritis Rheum. 19: 155–161.PubMedGoogle Scholar
  106. 106.
    Finch, W. R. and Strotmam, M. P., 1979, Acute adverse reactions to ibuprofen in systemic lupus erythematosus, JAMA 241: 2616–2618.PubMedGoogle Scholar
  107. 107.
    Hess, E. V. and Hahn, B., 1978, Influenze immunization in lupus erythematosus: Safe, effective ?, Ann. Intern. Med. 88: 833–834.PubMedGoogle Scholar
  108. 108.
    Klippel, J. H., Kirsh, J., Stahl, N. I., Decker, J. L., Steinberg, A. D., and Schiffman, G., 1979, A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus, Arthritis Rheum. 22: 1321–1325.PubMedGoogle Scholar
  109. 109.
    Alarcon-Segovia, D., 1975, Drug-induced systemic lupus erythematosus and related syndromes, Clin. Rheum. Dis. 1: 573–582.Google Scholar
  110. 110.
    Lee, S. L. and Chase, P. H., Drug induced systemic lupus: A critical review, Sem. Arth. Rheum. 5: 83–103.Google Scholar
  111. 111.
    Giansiracusa, D. F. and Kantrowitz, F. G., 1982, Systemic Lupus Erythematosus and drug-induced lupuslike syndromes, Rhemuatic and Matabolic Bone Diseases in the Elderly, The Collamore Press, Lexington, Massachusetts, pp. 69–82.Google Scholar
  112. 112.
    Rothfield, N. F., Bierer, W. F., and Garfield, J. W., 1978, Isoniazid induction of antinuclear antibodies, Ann. Intern. Med. 88: 650–652.PubMedGoogle Scholar
  113. 113.
    Blomgren, S. E., Condemi, J. J., and Bignall, M. C., 1969, Antinuclear antibody induced by procainamide. A prospective study, N. Engl. J. Med. 281: 64–66.PubMedGoogle Scholar
  114. 114.
    Hildreth, E. A., Biro, C. E., and McCreary, T. A., 1960, Persistence of the “hydralazine syndrome”: A follow-up study of eleven cases, JAMA 173: 657–660.Google Scholar
  115. 115.
    Perry, H. M., Jr., 1972, Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis, Am. J. Med. 54: 58–72.Google Scholar
  116. 116.
    Alarcon-Segovia, D., Fishbein, E., and Alcala, H., 1971, Isoniazid acetylation rate and development of antinuclear antibodies upon isoniazid therapy, Arthritis Rheum. 14: 748–752.PubMedGoogle Scholar
  117. 117.
    Perry, J. M., Jr., Tan., E. M., Garmody, S., and Sakamoto, A., 1970, Relationship of acetyltransferase activity to anti-nuclear and toxic symptoms in hypertensive patients treated wtih hydralazine, J. Lab. Clin. Med. 76: 114–125.Google Scholar
  118. 118.
    Woolsey, R. L., Drayer, D. E., Reidenberg, M. M., Nies, A. S., Carr, K., and Oates, J. A., 1978, Effect of acetylator phenotype on the rate at which procainamide induces anti-nuclear antibodies and the lupus syndrome, N. Engl. J. Med. 298: 1157–1159.Google Scholar
  119. 119.
    Lahita, R., Kluger, J., and Drayer, D. E., 1979, Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide, N. Engl. J. Med. 301: 1387–1388.Google Scholar
  120. 120.
    Kluger, J., Drayer, D. E., Reidenberg, M. M. and Lahita, R., 1981, Acetylprocainamide therapy in patients with previous procainamide-induced lupus syndrome, Ann. Intern. Med. 95: 18–23.PubMedGoogle Scholar
  121. 121.
    Reza, M. J., Dornfeld, L., and Goldberg, L. S., 1975, Hydralazine therapy in hypertensive patients with idiopathic systemic lupus erythematosus, Arthritis Rheum. 18: 335–338.PubMedGoogle Scholar
  122. 122.
    Blomgren, S. E., Gondemi, J. J., and Vaugh, J. H., 1972, Procainamide-induced lupus erythematosus: Clinical and laboratory observations, Am. J. Med. 52: 338–348.PubMedGoogle Scholar
  123. 123.
    Giansiracusa, D. F. and Kantrowitz, F. D., 1982, Sjogren Syndrome, Rheumatic and Metabolic Bone Diseases in the Elderly, The Collamore Press, Lexington, Massachusetts, pp. 83–90.Google Scholar
  124. 124.
    Whaley, K., Williamson, J., Wilson, T., McGavin, M. M., Hughes, G. R. U., Hughes, H., and Schmulian, L. R., 1972, Sjogren’s syndrome and autoimmunity in the geriatric population, Age Aging, 1: 197–206.Google Scholar
  125. 125.
    Forstot, J. Z., Forstot, S. L., Greer, R., and Tan, E. M., 1982, The incidence of Sjorgen’s sicca complex in a population of patients with keratoconjunctivitis sicca, Arthritis Rheum. 25: 156–160.PubMedGoogle Scholar
  126. 126.
    Daniels, T. E., Powell, M. R., Sylvester, R. A., and Talal, N., 1979, An evaluation of salivary scintigraphy in Sjogren’s syndrome, Arthritis Rheum. 22: 809–814.PubMedGoogle Scholar
  127. 127.
    Greenspan. J. S., Daniels, T. E., Talal, N., and Sylvester, R. A., 1974, The histopathology of Sjogren’s syndrome in labial salivary gland biopsies, Oral Surg. 37: 217–229.Google Scholar
  128. 128.
    Daniels, T. E., Silverman, S., Michalski, J. P., Greenspan, J. S., Sylvester, R. A., and Talal, N., 1975, The oral component of Sjogren’s syndrome, Oral Surg. 39: 875–885.PubMedGoogle Scholar
  129. 129.
    Daniels, T. E., 1984, Labial salivary gland biopsy in Sjogren’s syndrome, Arthritis Rheum. 27: 147–156.PubMedGoogle Scholar
  130. 130.
    Michalski, J. P, Daniels, T. E, Talal, N., and Grey, H. M, 1975, Beta-2-microglobulin and lumphocytic infiltration in Sjogren’s syndrome, N. Engl. J. Med. 293: 1228–1231.PubMedGoogle Scholar
  131. 131.
    Korttinen, Y. T., Kulomaa, M., et al., 1984, Lactoferrin in Sjogren’s syndrome, Arthritis Rheum. 27: 462–467.Google Scholar
  132. 132.
    Strand, V. and Talal, N., 1979–80, Advances in the diagnosis and concept of Sjogren’s syndrome (autioimmune exocrinopathy), Bull. Rheum. Dis. 30: 1046–1052.Google Scholar
  133. 133.
    Whaley, K., Williamson, S., Chrisholm, D. M., Mason, D. K., and Buchanan, W. W., 1973, Sjogren’s Syndrome, Q. J. Med. 42: 279–304.Google Scholar
  134. 134.
    Anderson, L. G. and Talal, N., 1971, The spectrum of benign to malignant lymphoproliferation in Sjogren’s syndrome, Clin. Exp. Immunol. 9: 199–221.Google Scholar
  135. 135.
    Whaley, K., Webb, J., McAvoy, B. A., Hughes, G. R. V., Lee, P., MacSween, R. N. M., and Buchanon, W. N., 1973, Sjogren’s syndrome II. Clinical associations and immunological phenomena, Q. J. Med. 42: 513–548.Google Scholar
  136. 136.
    Kassan, S. S., Thomas, T. L., Moutsopoulos, H. M., Hoover, R., Kimberly, R. P., Budman, D. R., Costa, J., Decker, J. L., and Chused, T. M., 1978, Increased risk of lymphoma in sicca syndrome, Ann. Intern. Med. 89: 888–892.PubMedGoogle Scholar
  137. 137.
    Moutsopoulos, H. M., Chused, T. M., Mann, D. L., Klippel, J. H., Fauci, A. S., Frank, M. M., Lawley, J. J., and Hamburger, M. I., 1980, Sjogren’s syndrome (sicca syndrome): Current issues, Ann. Intern. Med. 92: 212–226.PubMedGoogle Scholar
  138. 138.
    Alspaugh, M. A., Talal, N., and Tan, E. M., 1976, Differentiation and characterization of autoantibodies and their antigens in Sjogren’s syndrome, Arthritis Rheum. 19: 216–222.PubMedGoogle Scholar
  139. 139.
    Hamburger, M. I., Moutsopoulos, H. M., Lawley, T. J., and Frank, M. M., 1979, Sjogren’s syndrome: A defect in reticuloendothelial system Fc-receptor-specific clearnace, Ann. Intern. Med. 91: 534–538.PubMedGoogle Scholar
  140. 140.
    Alexander, E. L., Arnett, F. C., Provost, T. T., and Stevens, M. B., 1983, Sjogren’s syndrome: Association of Anti-Ro (SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity, Ann. Intern. Med. 98: 155–159.PubMedGoogle Scholar
  141. 141.
    Wilson, R. W., Provost, T. T., et al., 1984, Sjogren’s syndrome—Influence of multiple HLAD region alloantigens on clinical and serologic expression, Arthritis Rheum. 27: 1245–1253.PubMedGoogle Scholar
  142. 142.
    Fox, R. I., Chan, R., et al., 1984, Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca, Arthritis Rheum. 27: 459–461.PubMedGoogle Scholar
  143. 143.
    Glenner, G. G., 1980, Amyloid deposits and amyloidosis: The B-fibrilloses, N. Engl. J. Med. 302:1283–1292, 1333–1343.Google Scholar
  144. 144.
    Skinner, M., Cohen, A. S., Shirahama, T., and Cathcart, E. S., 1974, P-component of amyloid: isolation, characterization and sequence analysis, J. Lab. Clin. Med. 84: 604-614.Google Scholar
  145. 145.
    Isersky, L., Erin, D., Page, A. L., Harada, M., and Glenner, G. G., 1972, Immunochemical cross reactions of human amyloid proteins with immunoglobulin light polypeptide chains, J. Immunol. 108: 486–493.PubMedGoogle Scholar
  146. 146.
    Rosenthal, C. and Franklin, E. C., 1975, Variations with age and disease of an amyloid A protein-related serum component, J. Clin. Invest. 55: 746–753.PubMedGoogle Scholar
  147. 147.
    Benson, M. D. and Cohen, A. S., 1979, Serum amyloid A protein in amyloidosis, rheumatic and neoplastic diseases, Arthritis Rheum. 22: 36–42.PubMedGoogle Scholar
  148. 148.
    Morrow, J. F., Stearman, R. S., Peltzman, C. G., and Potter, D. A., 1981, Induction of hepatic synthesis of serum amyloid A protein and actin, Proc. Natl. Acad. Set. USA 78: 4718–4722.Google Scholar
  149. 149.
    Selinger, M. J., McAdam, K. P. W. J., Kaplan, M. M., Bipe, J. D., Vogel, S. N., and Rosenstreich, D. L., 1980, Monokine-induced synthesis of serum amyloid A protein by hepatocytes, Nature 285: 498–500.PubMedGoogle Scholar
  150. 150.
    Cornwell III, G. G., Murdoch, W. L., Kyle, R. A., Westermark, P., and Pitkanen, P., 1983, Frequency and distribution of senile cardiovascular amyloid, Am. J. Med. 75: 618–623.PubMedGoogle Scholar
  151. 151.
    Westermark, P, Natvig, J. B., and Johansson, B., 1977, Characterization of an amyloid fibril protein from senile cardiac amyloid, J. Exp. Med. 146: 631–636.PubMedGoogle Scholar
  152. 152.
    Cohen, A. S. and Benson, M. D., 1975, Amyloid peripheral neruopathy, in: Peripheral Neuropathy ( P. T. Dyck, K. P. Thomas, and E. H. Lombert eds.), W. B. Saunders Company, Philadelphia, pp. 1076–1091.Google Scholar
  153. 153.
    Wright, J. R., Calkins, E., Breen, W. J., Stolte, G., and Schultz, R. T., 1969, Relationship of amyloid to aging, Medicine 48: 39–60.PubMedGoogle Scholar
  154. 154.
    Wright, J. R. and Calkins, E., 1975, Amyloid in the aged heart: Frequency and clinical significance, J. Am. Geriatr. Soc. 23: 97–103.PubMedGoogle Scholar
  155. 155.
    Prusiner, S. B., 1984, Some speculation about prions, amyloid, and Alzheimer’s disease, N. Engl. J. Med. 310: 661–663.PubMedGoogle Scholar
  156. 156.
    Mandybur, T. I., 1975, The incidence of cerebral amyloid angiopathy in Alzheimer’s disease, Neuropathy 25: 120–126.Google Scholar
  157. 157.
    Bandt, K., Cathcart, E. S., and Cohen, A. S., 1968, A clinical analysis of the course and prognosis of 42 patients with amyloidosis, Am. J. Med. 44: 955–969.Google Scholar
  158. 158.
    Pruzanski, W. and Katz, A., 1976, Clinical and laboratory findings in primary generalized and multiple-myeloma-related amyloidosis, Can. Med. Assoc. J. 115: 906–909.Google Scholar
  159. 159.
    Kyle, R. A. and Bayrd, E. D., 1975, Amyloidosis: Review of 236 cases, Medicine, 54: 271–299.PubMedGoogle Scholar
  160. 160.
    Ignaczak, T. F., 1981, Amyloidosis, in: Textbook in Rheumatology. ( W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, eds.), W. B. Saunders Company, Philadelphia, pp. 1511–1530.Google Scholar
  161. 161.
    Gordon, D. A., Pruzanski, W., Ogryzlo, M. A., and Little, H. A., 1973, Amyloid arthritis simulating rheumatoid disease in five patients with multiple myeloma, Am. J. Med., 55: 142–154.PubMedGoogle Scholar
  162. 162.
    Stenkvist, B., Westermark, P., and Wibell, L., 1974, Simple method of diagnostic screening for amyloidosis, Ann. Rheum. Dis. 33: 75–76.PubMedGoogle Scholar
  163. 163.
    Libbey, C. A., Canoso, J. M., Skinner, M. O. Sipe, J. D., and Cohen, A. S., 1981, Diagnosis of amyloidosis and differentiation of secondary amyloid by analysis of abdominal fat tissue aspirate, Arthritis Rheum. 24: 125 (abstract).Google Scholar
  164. 164.
    Greipp, P. R., 1984, Amyloidosis (AL) an approach to early diagnosis, Arch. Intern. Med. 144: 2145–2146.Google Scholar
  165. 165.
    Kula, R. W., Engel, W. K., and Live, B. R., 1977, Scanning for soft tissue amyloid, Lancet 1: 92–93.PubMedGoogle Scholar
  166. 166.
    Maule, W. F. and Martin, R. H., 1983, Primary cardiac amyloidosis: An angiocardiographic clue to early diagnosis, Ann. Intern. Med. 98: 177–180.PubMedGoogle Scholar
  167. 167.
    Scheinberg, M. A., Pernambrico, J. C., and Benson, M. D., 1984, DMSO and colchicine therapy in amyloid disease, Ann. Rheum. 43: 421–423.Google Scholar
  168. 168.
    Wyngaarden, J. B. and Kelley, W. N., 1976, Gout and Hyperuricemia, Grune and Stratton, New York.Google Scholar
  169. 169.
    Mikkelson, W., Dodge, II. J., Valkenburg, II., and Hines, S., 1965, The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia, Am. J. Med. 39: 242–251.Google Scholar
  170. 170.
    Hall, A. P., Barry, P. E. Dawber, T. R., and McNamara, P. M., 1967, Epidemiology of gout and hyperuricemia: A long-term population study. Am. J. Med. 42: 27–37.Google Scholar
  171. 171.
    O’Sullivan, J. B., 1972, Gout in a New England town: A prevalence study of uric acid levels in Sudbury, Massachusetts, Ann. Rheum. Dis. 31: 166–169.PubMedGoogle Scholar
  172. 172.
    Wilson, J. M., Young, A. B., and Kelley, W. N., 1983, Hypoxanthine guanine phosphoribosyltransferase, N. Engl. J. Med. 309: 900–910.PubMedGoogle Scholar
  173. 173.
    Berger, L. and Yu, T. F., 1975, Renal function in gout: An analysis of 524 gout subjects including long-term follow up, Am. J. Med. 56: 665–675.Google Scholar
  174. 174.
    Yu, T. A-F. and Berger, L., 1982, Impaired renal function in gout, Am. J. Med. 72: 95–99.PubMedGoogle Scholar
  175. 175.
    Reynolds, P. R., Knapp, M. J., Baraf, H. S. B., and Holmes, E. W., 1983, Moonshine and lead, Arthritis Rheum 26: 1057–1064.PubMedGoogle Scholar
  176. 176.
    Faller, J. and Fox, I. H., 1982, Ethanol-induced hyperuricemia, N. Engl. J. Med. 307: 1598–1602.PubMedGoogle Scholar
  177. 177.
    Rodman, G. P., 1980, The pathology of Alderman’s gout: Procatarotic role of fluc-tuations in serum urate concentration in gouty arthritis provoked by feast and alcohol, Arthritis Rheum. 23: 737 (abstract).Google Scholar
  178. 178.
    Snaith, M. L. and Scott, J. T., 1972, Uric acid excretion and surgery, Ann. Rheum. Dis. 31: 162–165.PubMedGoogle Scholar
  179. 179.
    Hadler, N. M., Franck, W. A., Bress, N. M., and Robinson, D. R., 1974, Acute polyarticular gout, Am. J. Med. 56: 715–719.PubMedGoogle Scholar
  180. 180.
    Agudelo, C. A., Weinberger, A., Schumacher, H. R., et al., 1979, Definitive diagnosis of gout by identification of urate crystals in asymptomatic metatarsophalangeal joints, Arthritis Rheum. 22: 559–560.PubMedGoogle Scholar
  181. 181.
    Gatter A., 1974, The compensated polarized light microscope in clinical rheumatology, Arthritis Rheum. 17: 253–255.PubMedGoogle Scholar
  182. 182.
    Freeman, D. L., 1983, Frequent doses of I.V. colchicine can be lethal (letter), N. Engl. J. Med. 309: 310.PubMedGoogle Scholar
  183. 183.
    Ciabattoni, G.,Cinotti, G. A., Pierucci, A., et al., 1984, Effects of sulindac and ibuprofen in patients with chronic glomerular disease. N. Engl. J. Med. 310: 279–283.PubMedGoogle Scholar
  184. 184.
    Hände, K. R., Noone, R. M., and Stone, W. J., 1984, Severe allopurinol toxicity, Am. J. Med. 76: 47–56.PubMedGoogle Scholar
  185. 185.
    Liang, M. W. and Fries, J. F., 1978, Asymptomatic hyperuricemia: The case for conservative management, Ann. Intern. Med. 88: 666–670.PubMedGoogle Scholar
  186. 186.
    Fessel, W. J., 1979, Renal outcomes in gout and hyperuricemia, Am. J. Med. 67: 74–82.PubMedGoogle Scholar
  187. 187.
    Gutman, A. B., 1972, Medical management of gout. Postgrad. Med. 51: 61–66.PubMedGoogle Scholar
  188. 188.
    Kelley, W. N., 1981, Approach to the patient with hyperuricemia, in: Textbook of Rheumatology ( W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, eds.), W. B. Saunders Company, Philadelphia, pp. 494–500.Google Scholar
  189. 189.
    McCarty, D. J., 1976, Calcium pyrophosphate dehydrate deposition disease, 1975, Arthritis Rheum. 19: 275–285.PubMedGoogle Scholar
  190. 190.
    Rubenstein, H. M. and Shah, D. M., 1972–1973, Pseudogout, Sem Arth. Rheum. 2: 259–280.Google Scholar
  191. 191.
    Ellman, M. H. and Levin, B., 1975, Chondrocalcinosis in elderly persons, Arthritis Rheum. 18: 43–47.PubMedGoogle Scholar
  192. 192.
    O’Duffy, J. D., 1976, Clinical studies of acute pseudogout attacks, Arthritis Rheum. 19: 349–352.PubMedGoogle Scholar
  193. 193.
    McCarty, D. J. and Kozin, F., 1975, An overview of cellular and molecular mechanisms in crystal-induced inflammation, Arthritis Rheum. 18: 757–765.PubMedGoogle Scholar
  194. 194.
    Howell, D. S., 1981, Diseases due to the deposition of calcium pyrophosphate and hydroxyapatite, in: Textbook of Rheumatology ( W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, eds.), W. B. Saunders Company, Philadelphia, pp. 1438–1456.Google Scholar
  195. 195.
    Vanderkorst, J. and Geerards, J., 1976, Articular chondrocalcinosis in a Dutch pedigree, Arthritis Rheum. 19: 405–409.Google Scholar
  196. 196.
    Reginato, A. M., 1976, Articular chondrocalcinosis in the Chiloe islanders, Arthritis Rheum. 19: 395–404.PubMedGoogle Scholar
  197. 197.
    Bjelle, A., Edvinsson, U., and Hagstun, A., 1982, Pyrophosphate anthropathy in two Swedish families, Arthritis Rheum. 25: 66–74.PubMedGoogle Scholar
  198. 198.
    Lust, G., Faure, G., Nelter, P., Gaucher, A., and Seegmiller, J. E., 1981, Evidence of a generalized metabolic defect in patients with hereditary chondrocalcinosis, Arthritis Rheum. 24: 1517–1521.PubMedGoogle Scholar
  199. 199.
    Hamilton, E. B. D., 1976, Dieseases associated with calcium pyrophosphate dihydrate deposition disease, Arthritis Rheum. 19: 353–357.PubMedGoogle Scholar
  200. 200.
    Howell, D. S., Muniz, O., Pita, J. L., and Enis, J. E., 1976, Pyrophosphate release by osteoarthritis cartilage incubates, Arthritis Rheum. 19: 488–494.PubMedGoogle Scholar
  201. 201.
    Tennenbaum, J., Muniz, O., and Schumacher, H. R., 1981, Comparison of phosphohydrolase activities from articular cartilage in calcium pyrophosphate dihydrate depositon disease and primary osteoarthritis, Arthritis Rheum. 24: 492–500.Google Scholar
  202. 202.
    Genant, H. K., 1976, Roentgenographic aspects of calcium pyrophosphate dihydrate crystal deposition disease, Arthritis Rheum. 19: 307–328.PubMedGoogle Scholar
  203. 203.
    Resnick, D., Nuwayama, G., Goergen, T. G., Utsinger, P. D., Shapiro, R. F., Haselwood, D. H., and Wiesner, K. B., 1977, Clinical, radiographic, and patho logic abnormalities in calcium pyrophosphate dihydrate deposition disease (CPPD): Pseudogout, Radiology 12: 1–16.Google Scholar
  204. 204.
    McCarty, D. J. and Gatter, R. A., 1966, Recurrent acute inflammation associated with focal apatite crystal deposition, Arthritis Rheum. 9: 804–819.PubMedGoogle Scholar
  205. 205.
    Dieppe, P. A., Crocker, P., Huskisso, E. C., and Willoughby, D. A., 1976, Apatite deposition disease—A new anthropathy?, Lancet 1: 266–269.PubMedGoogle Scholar
  206. 206.
    Schumacher, H. R., Somlyo, A. P., Tse, R. L., and Maurer, K., 1977, Arthritis associated with apatite crystal, Ann. Intern. Med. 87: 411–416.PubMedGoogle Scholar
  207. 207.
    Fam, A. G., Pritzker, K. P. H., Stein, J. L., Houpt, J. B., and Little, A. H., 1979, Apatite-associated arthropathy: A clinical study of 14 cases and of 2 patients with calcific bursitis, J. Rheumatol. 6: 461–471.PubMedGoogle Scholar
  208. 208.
    Paul, H., Resinato, A. J., and Schumacher, H. R., 1983, Alizarin red S staining as a screening test to detect calcium compounds in synovial fluid, Arthritis Rheum. 26: 191–200.PubMedGoogle Scholar
  209. 209.
    Good, A. E., Rozboril, M. B., Port, F. G., et al., 1982, The dialysis shoulder (abstr.), Arthritis Rheum. 25: 534.Google Scholar
  210. 210.
    Brandt, K. D. and Krey, P. R., 1977, The result of massive synovial deposition of calcium apatite in progressive systemic sclerosis, Arthritis Rheum. 20: 792–796.PubMedGoogle Scholar
  211. 211.
    Schumacher, H. R., Schimmer, B., Gordon, G. V., et al., 1979, Articular manifestations of polymyositis and dermatomyositis, Am. J. Med. 67: 289–292.Google Scholar
  212. 212.
    Halverson, P. B., McCarty, D. J., Cheung, H. S., and Ryan, L. M., 1984, Milwaukee shoulder syndrome, Semin. Arth. Rheum. 14: 36–144.Google Scholar
  213. 213.
    Goldberg, M. A. and Schumacher, H. R., 1977, Heterotopic ossification mimicking acute arthritis after neurologic catastrophies, Arch. Intern. Med. 137: 619–621.Google Scholar
  214. 214.
    Sorensen, P. S. and Lorenzen, I., 1977, Temporal arteritis and polymyalgia rheumatica, Acta. Med. Scand. 201: 207–213.Google Scholar
  215. 215.
    Ettlinger, R. E., Hunder, G. G., and Ward, L. E., 1978, Polymyalgia rheumatica and giant cell arteritis, Ann. Rev. Med. 29: 15–22.PubMedGoogle Scholar
  216. 216.
    Goodman, B. W., 1979, Temporal arteritis, Am. J. Med. 67: 839–852.PubMedGoogle Scholar
  217. 217.
    Bengtsson, B. and Malmwall, B., 1981, The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Arthritis Rheum. 24: 899–904.PubMedGoogle Scholar
  218. 218.
    Huston, K. A., Hunder, G. G., Lie, J. T., Kennedy, R. H., and Elveback, L. R., 1978, Temporal arteritis: A 25 year epidemiologic, clinical, and pathologic study, Ann. Intern. Med. 88: 162–167.PubMedGoogle Scholar
  219. 219.
    Calamia, K. T. and Hunder, G. G. 1980, Clinical manifestations of giant cell arteritis, Clin. Rheum. Dis. 6: 389–403.Google Scholar
  220. 220.
    Spiera, H. and Davison, S., 1982, Treatment of polymyalgia rheumatica (letter), Arthritis Rheum. 25: 120.PubMedGoogle Scholar
  221. 221.
    Hall, S., Lie, S. T., Kurlend, L. T., et al., 1983, The therapeutic impact of temporal artery biopsy, Lancet 2: 1217–1220.PubMedGoogle Scholar
  222. 222.
    O’Duffy, D. J., Wanner, H. W., and Hunder, G. G., 1976. Joint imaging in polymyalgia rheumatica, Mayo Clin. Proc. 51: 519–524.Google Scholar
  223. 223.
    Hunder, G. G. and Hazleman, B. L., 1981. Giant cell arteritis and polymyalgia rheumatica, in: Textbook of Rheumatology (W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, eds.), W. B. Saunders Company, Philadelphia, pp. 1189–1198.Google Scholar
  224. 224.
    Healey, L. A., 1984, Longterm follow-up of polymyalgia rheumatica: Evidence for synovitis, Semin. Arth. Rheum. 13: 322–328.Google Scholar
  225. 225.
    Henderson, D. R. F., Tribe, C. R., and Dixon, A. S. J., 1975, Synovitis in polymyalgia rheumatica, Rheum. Rehabil. 14: 244–250.Google Scholar
  226. 226.
    Giansiracusa, D. F. and Kantrowitz, F. G., 1982, Polymyaglia rheumatica and giant cell arteritis, in: Rheumatica and Metabolic Bone Disease in the Elderly, The Collamore Press, Lexington, Massachusetts, pp. 97–105.Google Scholar
  227. 227.
    Hunder, G. G. and Allen, G. L., 1978-1979, Giant cell arteritis: A review, Bull. Rheum. Dis. 29: 980–987.Google Scholar
  228. 228.
    Williamson, I. M. S. and Russel, R. W. R., 1972, Arteritis of the head and neck in giant cell arteritis: A pathological study to show the pattern of arterial involvement. Arch Neruol. 27: 378–391.Google Scholar
  229. 229.
    Small, P., 1984, Giant cell arteritis presenting as bilateral stroke. Arthritis Rheum. 7: 819–821.Google Scholar
  230. 230.
    Klein, R. G., Hunder, G. G., Stanson, A. W., and Sheps, S. G., 1975, Larger artery involvement in giant cell (temporal) arteritis, Ann. Intern. Med. 83: 806–812.PubMedGoogle Scholar
  231. 231.
    Healy, L. A. and Wilske, K. R., 1980, Presentation of occult giant cell arteritis, Arthritis Rheum. 23: 641–643.Google Scholar
  232. 232.
    Calamia, K. T. and Hunder, G. G., 1981, Giant cell arteritis (temporal arteritis) presenting as fever of unknown origin, Arthritis Rheum. 24: 1414–1418.PubMedGoogle Scholar
  233. 233.
    Long, R. and James, O., 1974, Polymyalgia rheumatica and liver disease, Lancet i. 77–79.Google Scholar
  234. 234.
    Litwack, K. D., Bohan, A., and Silverman, L., 1977, Granulomatous hepatitis and giant cell arteritis, J. Rheumatol. 4: 307–312.PubMedGoogle Scholar
  235. 235.
    Banks, P. M., Cohen, M. D., Ginsburg, W. W., and Hunder, G. G., 1983, Immunologic and cytochemical studies of temporal arteritis, Arthritis Rheum. 26: 1201–1207.PubMedGoogle Scholar
  236. 236.
    Morgan. J. G. and Harris, E. D., 1978, Non-giant cell temporal arteritis, Arthritis Rheum. 21: 362–366.Google Scholar
  237. 237.
    Klein, R. G., Campbell, R. J., Hunder, G. G., and Carney, J. A., 1976, Skip lesions in temporal arteritis, Mayo Clin. Proc. 51: 504–510.Google Scholar
  238. 238.
    Allison, M. C. and Gallagher, P. J., 1984, Temporal artery biopsy and corticosteroid treatment, Ann. Rheum. Dis. 43: 416–417.PubMedGoogle Scholar
  239. 239.
    Sewell, R. R., Allison, D. J., Tarin, D., and Hughes, G. L., 1980, Combined temporal arteriography and selective biopsy in suspected giant cell arteritis, Ann. Rheum. Dis. 39: 124–128.PubMedGoogle Scholar
  240. 240.
    Schneider, H. A., Weber, A. A., and Bailen, P. A., 1971, The visual prognosis in temporal arteritis, Ann. Ophthal. 3: 1215–1230.PubMedGoogle Scholar
  241. 241.
    Jones, J. G. and Hazleman, B. L., 1981, Prognosis and management of polymyalgia rheumatica. Ann. Rheum. Dis. 40: 1–5.PubMedGoogle Scholar
  242. 242.
    Lockshin, M. D., 1970, Diplopia as an early sign of temporal arteritis, Arthritis Rheum, 13: 419–421.PubMedGoogle Scholar
  243. 243.
    Wright, V., 1978, Seronegative polyarthritis, Arthritis Rheum. 21: 619–633.PubMedGoogle Scholar
  244. 244.
    Calin, A., 1981, Ankylosing spondylitis, in: Textbook of Rheumatology ( W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, eds.), W. B. Saunders Company, Philadelphia, pp. 1017–1032.Google Scholar
  245. 245.
    Moll, J. M. H., Haslock, I., MacRae, I. F., and Wright, V., 1974, Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome, Medicine 53: 343–364.PubMedGoogle Scholar
  246. 246.
    Marks, S. H., Barnett, M., and Calin, A., 1982, A case-control study of juvenile- and-adult-onset ankylosing spondylitis, J. Rheumatol. 9: 739–741.PubMedGoogle Scholar
  247. 247.
    Kellgren, J. H., 1964, The epidemiology of rheumatic diseases, Ann. Rheum. Dis. 23: 109 - 122.PubMedGoogle Scholar
  248. 248.
    Carter, E. T., McKenna, C. H., Brian, D. D., and Kurland, L. T., 1979, Epidemiology of ankylosing spondylitis in Rochester, Minnesota, 1935–1973, Arthritis Rheum. 22: 315–370.Google Scholar
  249. 249.
    Baum, J. and Ziff, M., 1971, The rarity of ankylosing spondylitis in the black race, Arthritis Rheum. 14: 12–18.PubMedGoogle Scholar
  250. 250.
    Carette, S., Graham, D., Little, H., Rubenstein, J., and Rosen, P., 1983, The natural disease course of ankylosing spondylitis, Arthritis Rheum. 26: 186–190.PubMedGoogle Scholar
  251. 251.
    Ginsburg, W. W. and Cohen, M. D., 1983, Peripheral arthritis in ankylosing spondylitis: A review of 209 patients followed up for more than 20 years, Mayo Clin. Proc. 58: 593–596.Google Scholar
  252. 252.
    Gran, J. T. and Husby, G., 1984, Ankylosing spondylitis: A comparative study of patients in an epidemiological survey, and those admitted to a department of rheumatology, J. Rheumatol. 11: 788–793.PubMedGoogle Scholar
  253. 253.
    Khan, M. A., Braun, W. E., Kushner, I., Grecek, D. E., Muir, W. A., and Steinberg, A. G., 1977, HLA B27 in ankylosing spondylitis: Differences in frequency and relative risk in American Blacks and Caucasians, J. Rheumatol. 4 (suppl 3): 39–43.Google Scholar
  254. 254.
    Calin, A., Marder, A., Becks, E., and Burns, T., 1983, Genetic differences between B27 positive patients with ankylosing spondylitis and B27 positive healthy controls, Arthritis Rheum. 26: 1460–1464.PubMedGoogle Scholar
  255. 255.
    van der Linden, S. M., Valkenburg, H. A., de Jongh, B. M., and Cats, A., 1984, The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: A comparison of relatives of spondylitis patients with the general population, Arthritis Rheum. 27: 241–249.Google Scholar
  256. 256.
    LeClerq, S. A. and Russell, A. S., 1984, The risk of sacroilitis in B27 positive persons: A reappraisal, J. Rheumatol. 11: 327–329.Google Scholar
  257. 257.
    van der Linden, S. M. and Khan, M. A., 1984, The risk of ankylosing spondylitis in HLA-B27 positive individuals: A reappraisal, J. Rheumatol. 11: 727–728.PubMedGoogle Scholar
  258. 258.
    Marks, S. H., Barnett, M., and Calin, A., 1983, Ankylosing spondylitis in women and men: A case-control study, J. Rheumatol. 10: 624–628.PubMedGoogle Scholar
  259. 259.
    Polley, H. F. and Slocumb, C. H., 1947, Rheumatoid spondylitis: A study of 1,035 cases, Ann. Intern. Med. 26: 240–249.PubMedGoogle Scholar
  260. 260.
    Wilkinson, M. and Bywaters, E. G. L., 1958, Clinical features and course of anky-losing spondylitis: As seen in a follow-up of 222 hospital referred cases, Ann. Rheum. Dis. 17: 209–228.PubMedGoogle Scholar
  261. 261.
    Calin, A., Porta, J., Fries, J. F., and Schurman, D. J., 1977, Clinical history as a screening test for ankylosing spondylitis, JAMA 237: 2613–2614.PubMedGoogle Scholar
  262. 262.
    Resnick, D., Dwosh, I. L., Goergen, T. G., Shapiro, R. F., Utsinger, P. D., Wiesner, K. B., and Bryan, B. L., 1976, Clinical and radiographic abnormalities in ankylosing spondylitis: A comparison of men and women, Radiology 119: 293–297.PubMedGoogle Scholar
  263. 263.
    Cohen, M. D. and Ginsburg, W. W., 1982, Late-onset peripheral joint disease in ankylosing spondylitis, Ann. Rheum. Dis. 41: 574–578.PubMedGoogle Scholar
  264. 264.
    Hart, F. D. and Robinson, K. C., 1959, Ankylosing spondylitis in women, Ann. Rheum. Dis. 18: 15–23.PubMedGoogle Scholar
  265. 265.
    Giansiracusa, D. F. and Kantrowitz, F. G., 1982, Seronegative spondyloarthropathies, in: Rheumatic and Metabolic Bone Diseases in the Elderly, The Collamore Press, Lexington, Mass., pp. 119–134.Google Scholar
  266. 266.
    Khan, M. A., Kushner, I., and Braun, W. E., 1977, Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis, Arthritis Rheum. 20: 909–912.PubMedGoogle Scholar
  267. 267.
    Hunter, T. and Dubo, H., 1978, Spinal fractures complicating ankylosing spondylitis, Ann. Intern. Med. 88: 546–549.PubMedGoogle Scholar
  268. 268.
    Murray, G. C. and Persellin, R. H., 1981, Cervical fracture complicating ankylosing spondylitis: A report of eight cases and review of the literature, Am. J. Med. 70: 1033–1041.PubMedGoogle Scholar
  269. 269.
    Hunter, T. and Dubo, H., 1983, Spinal fractures complicating ankylosing spondylitis: A long-term follow up study, Arthritis Rheum. 26: 751–759.PubMedGoogle Scholar
  270. 270.
    Graham, D. C. and Smythe, H. A., 1958, The carditis and aortitis of ankylosing spondylitis, Bull. Rheum. Dis. 9: 171–174.PubMedGoogle Scholar
  271. 271.
    Bulkley, B. H. and Roberts, W. C., 1973, Ankylosing spondylitis and aortic regur-gitation: Description of the characteristic cardiovascular lesion from study of eight necropsy patients, Circulation 48: 1014–1027.PubMedGoogle Scholar
  272. 272.
    Bergfeldt, L., Edhag, O., Vedin, L., and Vallin, H., 1982, Ankylosing spondylitis: An important cause of severe disturbances of the cardiac conduction system: Prevalence among 223 pacemaker-treated men, Am. J. Med. 73: 187–191.PubMedGoogle Scholar
  273. 273.
    Tucker, C. R., Fowles, R. E., Calin, A., and Popp, R. L., 1982, Aortitis in ankylosing spondylitis: Early detection of aortic root abnormalities with two dimensional echocardiography, Am. J. Cardiol 49: 680–686.PubMedGoogle Scholar
  274. 274.
    Rosenow, E. C., III, Strimlan, C. V., Muhm, J. R., and Ferguson, R. H., 1977, Pleuropulmonary manifestations of ankylosing spondylitis, Mayo Clin. Proc. 52: 641–649.Google Scholar
  275. 275.
    Russell, M. L., Gordon, D. A., Ogryzlo, M. A., and McPhedran, R. S., 1973, The cauda equina syndrome of ankylosing spondylitis, Ann. Intern. Med. 78: 551–554.PubMedGoogle Scholar
  276. 276.
    Gordon, A. L. and Yudell, A., 1973, Cauda equina lesion associated with rheumatoid spondylitis, Ann. Intern. Med. 78: 555–557.PubMedGoogle Scholar
  277. 277.
    Calin, A. and Marks, S., 1982, Management of ankylosing spondylitis, Bull. Rheum. Dis. 31: 35–38.Google Scholar
  278. 278.
    Altman, R. D. and Tennenbaum, J., 1981, Hypertrophic osteoarthropathy, in: Textbook of Rheumatology ( W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, eds.), W. B. Saunders Company, Philadelphia, pp. 1647–1657.Google Scholar
  279. 279.
    Schumacher, H. R., 1976, Articular manifestations of hypertrophic pulmonary osteoarthropathy in bronchogenic carcinoma, Arthritis Rheum. 19: 629–636.PubMedGoogle Scholar
  280. 280.
    Calabro, J. J., 1967, Cancer and arthritis, Arthritis Rheum. 10: 553–567.PubMedGoogle Scholar
  281. 281.
    Robinson, D. R. and Vickery, A. L., Jr., 1978, Case record, N. Engl. J. Med. 299: 708–714.Google Scholar
  282. 282.
    Evans, W. K., 1980, Reversal of hypertrophic osteoarthropathy after chemotherapy for bronchogenic carcinoma, J. Rheumatol. 7: 93–97.PubMedGoogle Scholar
  283. 283.
    Lopez-Enriquez, E. Morales, A. R., and Robert, F., 1980, Effect of atropine sulfate in pulmonary hypertrophic osteoarthropathy, Arthritis Rheum. 23: 822–824.Google Scholar
  284. 284.
    Auerback, M. D. and Brooks, P. M., 1981, Role of immune complexes in hypertrophic osteoarthropathy and non-metastatic polyarthritis, Ann. Rheum. Dis. 40: 470–472.Google Scholar
  285. 285.
    Rees, L., 1975, The biosynthesis of hormones by nonendocrine tumors, J. Endocrinol. 67: 143–175.PubMedGoogle Scholar
  286. 286.
    MacKenzie, A. H. and Scherbel, A. L., 1963, Connective tissue syndromes associated with carcinoma, Geriatrics 18: 745–753.PubMedGoogle Scholar
  287. 287.
    Sheon, R. P., Kirsner, A. B., Tangsintanapas, P., Samuel, F., Garg, M. L., and Finkel, R. I., 1977, Malignancy in rheumatic disease: Interrelationships, J. Am. Geriat. Soc. 25: 20–27.PubMedGoogle Scholar
  288. 288.
    Caldwell, D. S., 1981, Musculoskeletal syndromes associated with malignancy, Sem. Arth. Rheum 10: 198–223.Google Scholar
  289. 289.
    Bennett, R. M., Ginsberg, M. H., and Thomsea, S., 1976, Carcinomatous polyarthritis. The presenting symptoms of an ovarian tumor and associaton with platelet activating factor, Arthritis Rheum. 19: 953–958.PubMedGoogle Scholar
  290. 290.
    Isomaki, H. A., Mutru, O., and Koota, K., 1975, Death rates and causes of death in patients with rheumatoid arthritis, Scand. J. Rheumatol. 4: 205–208.PubMedGoogle Scholar
  291. 291.
    Lewis, R. B., Castor, C. W., Kinsley, R. E., and Boles, G. G., 1976, Frequency of neoplasia in systemic lupus erythematous and rheumatoid arthritis, Arthritis Rheum. 19: 1256–1260.PubMedGoogle Scholar
  292. 292.
    Kinlea, L. J., Sheil, A. G. R., Peto. J., and Doll, R., 1979. Collaborative United Kingdom-Australiasian study of cancer in patients treated with immunosuppressive drugs, Br. Med. J. 2: 1461–1466.Google Scholar
  293. 293.
    Lewis, D., Hazleman, B. L., Hanka, R., and Roberts, S., 1980, Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine, Ann. Rheum. Dis. 39: 457–461.PubMedGoogle Scholar
  294. 294.
    Bohan, A., Peter, J. B., Bowman, R. L., and Pearson, C. M., 1977, A computer- assisted analysis of 153 patients with polymyositis and dermatomyositis, Medicine 56: 255–286.PubMedGoogle Scholar
  295. 295.
    DeVere, R. and Bradley, W. G., 1975, Polymyositis: Its presentation, morbidity and mortality, Brain 98: 637–666.Google Scholar
  296. 296.
    Callen, J. P., Hyla, J. F. Boles, G. G., Jr., and Kay, D. R., 1980, The relationship of dermatomyositis and polymyositis to internal malignancy, Arch Derm. 116: 295–298.PubMedGoogle Scholar
  297. 297.
    Barnes, B. E., 1976, Dermatomyositis and malignancy: A review of the literature, Ann. Intern. Med. 84: 68–76.PubMedGoogle Scholar
  298. 298.
    Callen, J. P., 1981, The value of malignancy evaluation in patients with dermatomyositis, Arthritis Rheum. 24: S103 (abstract)Google Scholar
  299. 299.
    Bunch, T. W., 1981, Prednisone and azathioprine for polymyositis, Arthritis Rheum. 24: 45.PubMedGoogle Scholar
  300. 300.
    Metzger, A. L., Bohan, A., Goldberg, L. S., et al., 1974, Polymyositis and dermatomyositis, combined methotrexate and corticosteroid therapy, Ann. Intern. Med. 81: 182.PubMedGoogle Scholar
  301. 301.
    Murray, G. C. and Persellin, R. H., 1980, Metastatic carcinoma presenting as monoarticular arthritis, Arthritis Rheum. 23: 95–100.PubMedGoogle Scholar
  302. 302.
    Spilberg, I. and Meyer, G. J., 1972, The arthritis of leukemia, Arthritis Rheum. 15: 630–635.PubMedGoogle Scholar
  303. 303.
    Harden, E. A., Moore, J. O., and Haynes, B. F., 1984, Leukemia-associated arthritis: Identification of leukemic cells in synovial fluid using monoclonal and polyclonal antibodies, Arthritis Rheum. 27: 1306–1308.PubMedGoogle Scholar
  304. 304.
    Virshup, A. M. and Sliwinski, A. J., 1973, Polyarthritis and subcutaneous nodules in a patient with carcinoma of the pancreas, Arthritis Rheum. 16: 388–392.PubMedGoogle Scholar
  305. 305.
    Morgan, G. J., Jr., 1981, Panniculitis and erythema nodosum, in: Textbook of Rheumatology ( W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, eds.), W. B. Saunders Company, Philadelphia, pp. 1203–1207.Google Scholar
  306. 306.
    Medger, T. A., Jr., Dixon, J. A., Garwood, V. P., et al., 1982, Palmar fasciitis and polyarthritis associated with ovarian carcinoma, Ann. Intern. Med. 96: 424–431.Google Scholar
  307. 307.
    Michaels, R. M. and Sorber, J. A., 1984, Reflex sympathetic dystrophy as a probable paraneoplastic syndrome: Case report and literature review, Arthritis Rheum. 27: 1183–1185.PubMedGoogle Scholar
  308. 308.
    Taggart, A. J., Iveson, J. M. I., and Wright, V., 1984, Shoulder-hand syndrome and symmetrical arthralgia in patients with tubo-ovarian carcinoma, Ann. Rheum. Dis. 43: 391–303.PubMedGoogle Scholar
  309. 309.
    G. P. Rodnan and H. R. Schumacher, 1983, Osteoarthritis, in: Primer on the Rheumatic Diseases, Eighth ed., Arthritis Foundation, Atlanta, pp. 104–108.Google Scholar
  310. 310.
    Bland, J. H. and Cooper, S. M., 1984, Osteoarthritis: A review of the cell biology involved and evidence for reversibility. Management rationally related to known genesis and pathophysiology. Semin. Arthritis Rheum. 14: 106–133.PubMedGoogle Scholar
  311. 311.
    Hochberg, M. C., 1984, Osteoarthritis: Pathophysiology, clinical features, management, Hosp. Prac. 19: 41–53.Google Scholar
  312. 312.
    Mankin, H. J., 1974, The reaction of articular cartilage to injury and osteoarthritis, N. Engl. J. Med. 291:1285–1292, 1335–1340.Google Scholar
  313. 313.
    Gardner, D. L., 1983, The nature and causes of osteoarthrosis, Br. Med. J. 286: 418–424.Google Scholar
  314. 314.
    Kellgren, J. H. and Lawrence, J. S., 1958, Osteo-artrosis and disk degeneration in an urban population, Ann. Rheum. Dis. 17: 388–397.PubMedGoogle Scholar
  315. 315.
    Lawrence, J. S., Bremner, J. M., and Bier, F., 1966, Osteo-arthrosis: Prevalence in the population and relationship between symptoms and x-ray changes, Ann. Rheum. Dis. 25: 1–24.PubMedGoogle Scholar
  316. 316.
    Roughley, P. J. and White, R. J., 1980, Age-related changes in the structure of the proteoglycan subunits from human articular cartilage, J. Biol. Chem. 255: 217–224.PubMedGoogle Scholar
  317. 317.
    Muir, H., 1981, Proteoglycans: State of the art, Semin. Arthritis Rheum. 11: 7–10.Google Scholar
  318. 318.
    Radin, E. L., Paul, I. L., and Rose, R. M., 1972, Role of mechanical factors in pathogenesis of primary osteoarthritis, Lancet 1: 519–522.PubMedGoogle Scholar
  319. 319.
    Radin, E. L., 1976, Mechanical aspects of osteoarthritis, Bull. Rheum. Dis. 26: 862–865.PubMedGoogle Scholar
  320. 320.
    Brandt, K. D., 1981, Pathogenesis of osteoarthritis (OA), in: Textbook of Rheumatology ( W. N. Kelley, E. D. Harris, Jr., S. Ruddy, and C. B. Sledge, eds.), W. B. Saunders Company, Philadelphia, pp. 1457–1470.Google Scholar
  321. 321.
    Johnson, L. C., 1983, Structural dynamics of osteoarthritis, J. Rheumatol. 10 (suppl. 9): 22–24.Google Scholar
  322. 322.
    Venn, M. and Maroudas, A., 1977, Chemical composition and swelling of normal and osteoarthrotic femoral head cartilage, Ann. Rheum. Dis. 36: 121–129.PubMedGoogle Scholar
  323. 323.
    Venn, M. F., 1978, Variation of chemical composition with age in human femoral head cartilage, Ann. Rheum. Dis. 37: 168–174.PubMedGoogle Scholar
  324. 324.
    Perricone, E., Palmoski, M. J., and Brandt, K. D., 1977, Failure of proteoglycans to form aggregates in morphologically normal aged human hip cartilage, Arthritis Rheum. 20: 1372–1380.PubMedGoogle Scholar
  325. 325.
    Byers, P. D., Contepomi, C. A., and Farkas, T. A., 1970, A post mortem study of the hip joint including the prevalence of the features of the right side, Ann. Rheum. Dis. 29: 15–31.PubMedGoogle Scholar
  326. 326.
    Martel-Pelletier, J., Pelletier, J.-P., Cloutier, J. M., Howell, D. S., Ghandur-Mnaymneh, L., and Woessner, Jr., J. F., 1984, Neutral proteases capable of pro-teoglycan digesting activity in osteoarthritic and normal human articular cartilage, Arthritis Rheum. 27: 305–312.PubMedGoogle Scholar
  327. 327.
    Brandt, K. D. and Palmoski, M., 1976, Organization of ground substance proteoglycans in normal and osteoarthritic knee cartilage, Arthritis Rheum. 19: 209–215.PubMedGoogle Scholar
  328. 328.
    Lippiello, L., Hall, D., and Mankin, H. J., 1977, Collagen synthesis in normal and osteoarthritic human cartilage, J. Clin. Invest. 59: 593–600.PubMedGoogle Scholar
  329. 329.
    Pelletier, J.-P., Martel-Pelletier, J., Howell, D. S., Ghandur-Mnaymneh, L., Enis, J. E., and Woessner, Jr., J. F., 1983, Collagenase and collagenolytic activity in human osteoarthritic cartilage, Arthritis Rheum. 26: 63–68.PubMedGoogle Scholar
  330. 330.
    Broom, N. D., 1984, The altered biomechanical state of human femoral head osteoarthritic articular cartilage, Arthritis Rheum. 27: 1028–1039.PubMedGoogle Scholar
  331. 331.
    Bland, J. H. and Stulberg, S. D., 1981 Osteoarthritis: Pathology and clinical patterns, in: Textbook of Rheumatology ( W. N. Kelley, E. D. Harris, Jr. S. Ruddy, and C. B. Sledge, eds.), W. B. Saunders Company, Philadelphia, pp. 1471–1490.Google Scholar
  332. 332.
    Gardner, D. L., Oates, K., O’Connor, P., and Orford, C. R., 1983, The microscopic heterogeneity of osteoarthrosis, J. Rheumatol. 10 (suppl. 9): 9–10.Google Scholar
  333. 333.
    Mankin, H. J., 1983, Speculation regarding the biochemical pathogenesis of generalized osteoarthritis, J. Rheumatol. 10 (suppl. 9): 7–8.Google Scholar
  334. 334.
    Giansiracusa, D. F. and Kantrowitz, F. G., 1982, Articular cartilage: Changes associated with aging and osteoarthritis, in: Rheumatic and Metabolic Bone Diseases in the Elderly, The Collamore Press, Lexington, Mass., pp. 27–43.Google Scholar
  335. 335.
    Huskisson, E. C., Dieppe, P. A., Tucker, A. K., and Cannell, L. B., 1979, Another look at osteoarthritis, Ann. Rheum. Dis. 38: 423–428.PubMedGoogle Scholar
  336. 336.
    Peyron, J., 1981, Inflammation in osteoarthritis (OA): Review of its role in clinical picture, disease progress, subsets, and pathophysiology, Semin. Arthritis Rheum. 11: 115–116.Google Scholar
  337. 337.
    Goldenberg, D. L., Egan, M. S., and Cohen, A. S., 1982, Inflammatory synovitis in degenerative joint disease, J. Rheumatol. 9: 204–209.PubMedGoogle Scholar
  338. 338.
    Kellgren, J. H., 1983, Pain in osteoarthritis, J. Rheumatol. 10 (suppl. 9): 108–109.Google Scholar
  339. 339.
    Dieppe, P. A., Huskisson, E. C., Crocker, P., and Willoughby, D. A., 1976, Apatite deposition disease: A new arthropathy, Lancet 2: 266–269.Google Scholar
  340. 340.
    Schumacher, H. R., Smolyo, A. P., Tse, R. L., and Maurer, K., 1977, Arthritis associated with apatite crystals, Ann. Intern. Med. 87: 411–416.PubMedGoogle Scholar
  341. 341.
    Dieppe, P. A., 1981, Inflammation in osteoarthritis and the role of microcrystals, Semin. Arthritis Rheum. 11: 121–122.Google Scholar
  342. 342.
    Moskowitz, R. W., 1983, Which comes first: Inflammation or osteoarthritis ? J. Rheumatol. 10 (suppl. 9): 57–58.Google Scholar
  343. 343.
    Kellgren, J. H. and Moore, R., 1952, Generalized osteoarthritis and Heberden’s nodes, Br. Med. J. 1: 181–187.PubMedGoogle Scholar
  344. 344.
    Kellgren, J. H., 1961, Osteoarthrosis in patients and populations, Br. Med. J. 2: 1–6.PubMedGoogle Scholar
  345. 345.
    Stecher, R. M., 1955, Heberden’s nodes. A clinical descripton of osteoarthritis of the finger joints, Ann. Rheum. Dis. 14: 1–10.PubMedGoogle Scholar
  346. 346.
    Kellgren, J. H., Lawrence, J. S., and Bier, F., 1963, Genetic factors in generalized osteoarthrosis, Ann. Rheum. Dis. 22: 237–255.PubMedGoogle Scholar
  347. 347.
    Solomon, L., 1976, Patterns of osteoarthritis of the hip, J. Bone Joint Surg. 58B: 176–183.Google Scholar
  348. 348.
    Harris, W. H., 1983, Primary osteoarthritis of the hip: A vanishing diagnosis, J. Rheumatol. 10 (suppl. 9): 64.Google Scholar
  349. 349.
    Leach, R. E., Baumgard, S., and Broom, J., 1973, Obesity: Its relationship to osteoarthritis of the knee, Clin. Orthop. Rel. Res. 93: 271–273.Google Scholar
  350. 350.
    Moskowitz, R. W., 1982, Management of osteoarthritis, Bull. Rheum. Dis. 31: 31–35.Google Scholar
  351. 351.
    Doyle, D. V. and Lanham, J. G., 1984, Routine drug treatment of osteoarthritis, Chn. Rheum. Dis. 10: 277–291.Google Scholar
  352. 352.
    Giansiracusa, D. F. and Kantrowitz, F. G., 1982, Medication used in the management of rheumatic diseases, in: Rheumatic and Metabolic Bone Diseases in the Elderly, Collamore Press, Lexington, Mass. pp. 145–156.Google Scholar
  353. 353.
    Ouslander, J. G., Drug therapy in the elderly, 1981, Ann. Intern. Med., 95: 711–722.PubMedGoogle Scholar
  354. 354.
    Ferriera, S. H. and Vane, J. R., 1974, New aspects of the mode of action of non-steroidal anti-inflammatory drugs, Ann. Rev. Pharmacol. Toxicol. 14: 57–73.Google Scholar
  355. 355.
    Goodwid, J. S. and Ceuppens, J. L., 1983, Effect of nonsteroidal antiinflammatory drugs on immune function, Semin. Arthritis Rheum. 13 (supp. 1): 134.Google Scholar
  356. 356.
    Weissman, G. 1983, Pathways of archiadonate oxidation to prostaglandins and leukotrienes, Semin. Arthritis Rheum. 13 (suppl. 1): 123.Google Scholar
  357. 357.
    Weiss, B. and Hait, W. N., 1977, elective cyclic nucleotide phosphodieterase inhibitors as potential therapeutic agents, Ann. Rev. Pharmacol. Toxicol. 17: 441–447.Google Scholar
  358. 358.
    Lehmeyer, J. E. and Hohnston, R. B. Jr., 1978, Effect of anti-inflammatory drugs and agents that elevate intracellular cyclic AMP in the release of toxic oxygen metabolites by phagocytes: studies in a model of tissue bound IgG, Clin. Immunol. Immunopathol. 9: 482–490.Google Scholar
  359. 359.
    New drugs for arthritis, 1976, Med. Lett. 18: 77–79.Google Scholar
  360. 360.
    Simon, L. S. and Mills, J. A., 1980, Nonsteroidal anti-inflammatory drugs, N. Engl. J. Med. 302:1179–1185, 1237–1243.Google Scholar
  361. 361.
    Salem, S. and Stevenson, I. H., Absorption kinetics of aspirin and quinidine in elderly subjects, 1977, Br. J. Clin. Pharmacol., 4: 397 (abstr.).Google Scholar
  362. 362.
    Cuny, G., Rayer, R. J., Mur, J. M., et al., Pharmokinetics of salicylates in the elderly, 1979, Geronotology 25: 49–55.Google Scholar
  363. 363.
    Mongan, E., Kelly, P., Nies, L., et al., Tinnitus as an implication of therapeutic serum salicylate levels, 1973, JAMA 226: 142.PubMedGoogle Scholar
  364. 364.
    Woodbury, D. M., 1971, Analgesics, antipyretics, anti-inflammatory agents, and inhibitors or uric acid synthesis, in: The Pharmacological Basis of Therapeutics ( L. S. Goodman and A. Gilman, eds.), The MacMillan Co., New York, pp. 325–366.Google Scholar
  365. 365.
    Mann, N. S. and Sachdeu, A. J., 1977, Acute erosive gastritis, induced by aspirin, ketoprofen, ibuprofen, and naproxen; Its prevention by metiamide and cimetadine, South Med. J. 70: 562–564.Google Scholar
  366. 366.
    Baskin, W. N., Ivey, K. J., Krause, W. J., Jeffrey, G. E., and Gemmell, R. T., 1976, Aspirin-induced ultrastructural changes in human gastric mucosa, Ann. Intern. Med. 85: 299–303.PubMedGoogle Scholar
  367. 367.
    Kivilaakso, E. and Silen, W., 1979, Pathogenesis of experimental gastric-mucosal injury, N. Engl. J. Med. 301: 364–369.PubMedGoogle Scholar
  368. 368.
    Robert, A., 1976, Anti-secretory, antinulcer, cytoprotective and diarrheogenic properties of prostaglindins, Adv. Prostaglandin Thromboxane Res. 2: 507–521.Google Scholar
  369. 369.
    Johansson, C., Kollberg, B., Nordemar, R., and Bengstrom, S., 1979, Mucosal protection by prostaglandin E2, Lancet 1: 317.PubMedGoogle Scholar
  370. 370.
    Miller, T. A. and Jacobson, E. D., 1979, Gastrointestinal cytoprotection by prostaglandins, Gut 20: 75–87.PubMedGoogle Scholar
  371. 371.
    Bahrt, K. M., Korman, L. Y., and Nashel, D. J., 1984, Significance of a positive test for occult blood in stools of patients taking anti-inflammatory drugs. Arch. Intern. Med., 144: 2165.PubMedGoogle Scholar
  372. 372.
    Famaey, J. P. Brooks, P. M., and Carson, D. W., 1975, Biological effects on non-steroidal anti-inflammatory drugs, Sem. Arthr. Rheum. 5: 63–81.Google Scholar
  373. 373.
    Zucher, M. B. and Peterson, J., 1970, Effect of acetylsalicylic acid, other nonsteroidal anti-inflammatory agents, and dipyridanole in human blood platelets. J. Lab. Clin. Med. 76: 66–75.Google Scholar
  374. 374.
    Clive, D. M. and Stoff, J. S., 1984, Renal syndromes associated with nonsteroidal anti-inflammatory drugs, N. Engl. J. Med. 310: 563–572.PubMedGoogle Scholar
  375. 375.
    Kimberly, R. P., Bowden, R. E., Keisner, H. R., and Plotz, P. H., 1978, Reduction of renal function by newer nonsteroidal anti-inflammatory drugs, Am. J. Med. 64: 804–807.PubMedGoogle Scholar
  376. 376.
    Ciabattoni, G., Cinotti, G. A., et al., 1984, Effects of sulindac and ibuprofen in patients with chronic glomerular disease, N. Engl. J. Med. 310: 279–283.PubMedGoogle Scholar
  377. 377.
    Bunning, R. D. and Barth, W. F., 1982, Sulindac. A potentially renal sparing nonsteroidal anti-inflammatory drug. JAMA 248: 2864.PubMedGoogle Scholar
  378. 378.
    Toxicity of nonsteroidal anti-inflammatory drugs, 1983, Med. Lett. 25: 15.Google Scholar
  379. 379.
    Goodwin, J. S. and Regan, M., 1983, Cognitive dysfunction associated with naproxen and ibuprofen in the elderly, Arthritis. Rheum. 25: 1013–1015.Google Scholar
  380. 380.
    Huskisson, E. C., 1975, Anti-inflammatory drugs, Sem. Arthr. Rheum. 7: 1–20.Google Scholar
  381. 381.
    Fowler, P., 1975, Indomethacin and phenylbutazone, Clin. Rheum. Dis. 1: 267–283.Google Scholar
  382. 282.
    Szezeklik, A., Gryglewski, R. M., and Czerniawksa-Mysik, G., 1977, Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis, J. Allergy Clin. Immunol. 60: 276–284.Google Scholar
  383. 383.
    Weinberger, M., 1978, Analgesic sensitivity in children with asthma, Pediatrics 62: 910–915.PubMedGoogle Scholar
  384. 384.
    Salmon, J. E. and Kimberly, R. P., 1981, Formulary, in: Manual of Rheumatology and Outpatient Orthopedic Disorders ( J. F. Beary, C. C. Christian, and T. P. Sculco, eds.), Little Brown and Co., Boston, Massachusetts.Google Scholar
  385. 385.
    Wiseman, E. H. and Hobbs, D. C., 1982, Review of pharmacokinetic studies with Piroxicam, Am. J. Med. (Supplement) 2: 9–17.Google Scholar
  386. 386.
    Hoffman, L. M., Krupnick, M. I., and Garcia, H. A., 1972, Interactions of spironolactone and hydrochlorthiazide with aspirin in the dog and rat, J. Pharmacol. Exp. Ther. 180: 1–5.Google Scholar
  387. 387.
    Drug interactions update, 1984, Med. Lett. 26: 11.Google Scholar
  388. 388.
    Durao, V., Prata, M. M., and Goncalves, L. M. P., 1977, Modification of anti-hypertensive effect of B-adrenoreceptor-blocking agents by inhibition of endogenous prostaglandi synthesis, Lancet 2: 1005.PubMedGoogle Scholar
  389. 389.
    Smith, A., Mucklow, J. C., and Wandless, I., 1979, Compliance with drug treatment, Br. Med. J. 2: 1335–1336.Google Scholar
  390. 390.
    Axelrod, L., 1976, Glucocorticoid therapy, Medicine 55: 39–65.PubMedGoogle Scholar
  391. 391.
    Buckingham, R. B., 1978, Interactions involving anti-rheumatic agents, Bull. Rheum. Dis. 28: 960–966.Google Scholar
  392. 392.
    Hahn, T. J. and Hahn, B. H., 1976, Osteopenia in patients with rheumatic disease: Principles of diagnosis and therapy, Sem. Arthr. Rhuem. 6: 165–188.Google Scholar
  393. 393.
    Fucik, R. F., Kukreja, S. C., Hargis, G. K., Bowser, E. N., Hunderson, W. J., and Williams, G. A., 1975, Effect of glucocorticoids in function of the parathyroid glands in man, J. Clin. Endocrinol. Metab. 40: 152–155.PubMedGoogle Scholar
  394. 394.
    Harris, E. D., 1983, Glucocorticoid use in rheumatoid arthritis, Hosp. Pract. 18: 137–146.Google Scholar
  395. 395.
    Claman, H. N., 1983, Clucocorticosteroids II: The clinical responses, Hosp. Pract. 18: 143–151.Google Scholar
  396. 396.
    Fauci, A. S., Dale, D. C., and Balow, J. E., 1976, Glucocorticosteroid Therapy: Mechanisms of action and clinical considerations, Hosp. Pract. 84: 304–315.Google Scholar
  397. 397.
    MacKenzie, A. H., 1983, Antimalarial drugs for rheumatoid arthritis, Am. J. Med. in Oral gold therapy in rheumatoid arthritis: Auranofin, 75: 48–58.Google Scholar
  398. 398.
    MacKenzie, A. M., 1983, Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials, Am. J. Med., in: A reassessment of plaquenil in the treatment of rheumatoid arthritis, 75: 40–45.Google Scholar
  399. 399.
    MacKenzie, A. H. and Scherbel, A. L., 1980, Chloroquine and hydroxychloroquine in rheumatological therapy. Clin. Rheum. Dis. 6 (3): 545–566.Google Scholar
  400. 400.
    Fabre, J., De Freudenreich, J., Duckert, A., et al., 1966, Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines, and methacycline. Helv. Med. Acta 33: 307–316.Google Scholar
  401. 401.
    Sigler, J. W., Bluhn, G. B., Duncan, H., et al., 1974, Gold salts in the treatment of rheumatoid arthritis. Ann. Intern. Med. 80: 21–26.PubMedGoogle Scholar
  402. 402.
    Research subcommittee of the empire rheumatism council: Gold therapy in rheumatoid arthritis. Report of a multicentre controlled trial, 1961, Ann. Rheum. Dis. 20: 315–334.Google Scholar
  403. 403.
    Cooperating clinics committee of the American rheumatism association: A controlled trial of gold salt therapy in rheumatoid arthritis, 1973, Arthritis Rheum. 16: 353–358. 248Google Scholar
  404. 404.
    Kean, W. F., Bellamy, N., and Brooks, P. M., 1983, Gold therapy in the elderly rheumatoid arthritis patient, 26: 705–711.Google Scholar
  405. 405.
    Gottlieb, W. C. and Brown, H. E., 1972, Acute myocardial infarction following gold sodium thiomalate induced vasomotor (nitritoid) reaction, Arthritis Rheum. 20: 1026–1028.Google Scholar
  406. 406.
    Lintz, R. M., 1941, Toxic reactions with gold salts in treatment of rheumatic arthritis, J. Lab. Clin. Med. 26: 1629–1624.Google Scholar
  407. 407.
    Williams, H. J., 1982, A controlled clinical trial of auranofin, gold sodium thiomalate (GTM) and placebo in rheumatoid arthritis (abstr.), Arthritis Rheum. 75: 568.Google Scholar
  408. 408.
    Wenger, M. E., et al., 1983, Auranofin versus placebo in the treatment of rheumatoid arthritis, Am. J. Med. 75: 123–127.PubMedGoogle Scholar
  409. 409.
    Gofton, J. P., O’Brien, W. M., Hurley, J. N., et. al., 1984, Radiographic evaluation of erosion in rheumatoid arthritis: Double blind study of auranofin vs. placebo, J. Rheum. 11: 768–771.PubMedGoogle Scholar
  410. 410.
    Jaffe, I. A., 1977-1978, D-Pencillamine, Bull. Rheum. Dis. 28: 948–952.Google Scholar
  411. 411.
    Jaffe, I. A., 1983, Penicillamine: An anti-rheumatoid drug, Am. J. Med., 75: 63–67.PubMedGoogle Scholar
  412. 412.
    Rothermich, N. O., Thomas, H., Phillips, V. K., et al., 1981, Clinical trials of pencillamine in rheumatoid arthritis, Arthritis Rheum. 24: 1473–1478.PubMedGoogle Scholar
  413. 413.
    Decker, J. L., 1983, Azathioprine and cyclophosphamide as slow-acting drugs for rheumatoid arthritis, Am. J. Med. 75: 74–78.PubMedGoogle Scholar
  414. 414.
    Ward, J. R. and Williams, H. J., 1982, Interim observations on benefit/risk, of azathioprine versus D-pencillamine in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 41 (suppl.): 23–25.PubMedGoogle Scholar
  415. 415.
    Currey, H. L. F., Harris, J., Mason, R. M., et al., 1974, Comparison of azathioprine, cyclophosphamide and gold in treatment of rheumatoid arthritis, Br. Med. J. 3: 763–766.PubMedGoogle Scholar
  416. 416.
    Hoffmeister, R. T., 1983, Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am. J. Med. 75: 69–73.PubMedGoogle Scholar
  417. 417.
    Thompson, R. N., Watts, C. Edelman, J., et al., 1984, A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis, J. Rheum. 11: 760–763.PubMedGoogle Scholar
  418. 418.
    Groff, G. D., Shenberger, K. N., Wilke, W. S., et al., 1983, Low dose oral methotrexate in rheumatoid arthritis: An uncontrolled trial and review of the literature, Sem. Arth. Rheum. 12: 333.Google Scholar
  419. 419.
    Cupps, T. R. and Fauci, A. S., 1981, Management and treatment, in: The Vasculitides, Prob. Intern. Med. 21: 168.Google Scholar
  420. 420.
    Cristophidis, N., 1984, Methotrexate, Clin. Rheum. Dis. 10: 401–415.Google Scholar
  421. 421.
    Greenberg, M. S. and Zambrano, S. S., 1972, Aplastic agranulocytosis after allopurinol therapy, Arthritis Rheum. 15: 413–416.PubMedGoogle Scholar
  422. 422.
    Boston collaborative drug surveillance program, 1972, Excess of ampicillin rashes asssociates with allopurinol or hyperuricemia, N. Engl. J. Med. 286: 505–507.Google Scholar
  423. 423.
    Hande, K., R., Noone, R. M., and Stone, W. J., 1984, Severe allopurinol toxicity, Am. J. Med. 76: 47–56.Google Scholar
  424. 424.
    Young, J. L., Boswell, R. B., and Nies, A. S., 1974, Severe allopurinol hypersensitivity; association with thiazides and prior renal compromise, Arch. Intern. Med. 134: 553–558.Google Scholar
  425. 425.
    Brooks, P. M., Kean, W. F., Cassman, Y., et al., 1984, Problems of antiarthritic therapy in the elderly, J. Am. Geriatr. Soc. 32: 229–234.PubMedGoogle Scholar
  426. 426.
    Pasero, G., 1984, Colchicine: Should we still use it? Clin. Exp. Rheum. 2: 103–104.Google Scholar
  427. 427.
    Stanley, M. W., Taurog, J. D. and Snover, D. C., 1984, Fatal colchicine toxicity: Report of a case, Clin. Exp. Rheum. 2: 167–171.Google Scholar
  428. 428.
    Ferrannini, E. and Pentimone, F., 1984, Marrow aplasia following colchicine treatment for gouty arthritis, Clin. Exp. Rheum. 2: 173–175.Google Scholar
  429. 429.
    Giansiracusa, D. F. and Kantrowitz, F. G., 1982, Raynaud phenomenon in Rheumatic and Metabolic Bone Diseases in the Elderly, The Collamore Press, Lexington, Mass., pp. 91–95.Google Scholar
  430. 430.
    Spencer-Green, G., 1984, Raynaud phenomenon, Bull. Rheum. Dis. 33: 1–8.Google Scholar
  431. 431.
    Chen, Z.-Y., Silver, R. M., Ainsworth, S. K., Dobson, R. L., Rust, P., and Maricq, H. R., 1984, Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders, Am. J. Med. 77: 812–822.PubMedGoogle Scholar
  432. 432.
    Zweifler, A. J. and Trinkaus, P., 1984, Occlusive digital artery disease in patients with Raynaud’s phenomenon Am. J. Med. 77: 995–1001.PubMedGoogle Scholar
  433. 433.
    Kahan, A., Amor, B., and Menkes, C. J., 1984, Nifedipine treatment for Raynaud’s phenomenon (letter), Arthritis Rheum. 27: 959–960.PubMedGoogle Scholar
  434. 434.
    Sauza, J., Kraus, A., Gonzalez-Amaro, R., and Alarcon-Segovia, D., 1984, Effect of the calcium channel blocker nifedipine on Raynaud’s phenomenon. A controlled double blind trial, J. Rheumatol. 11: 362–364.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1986

Authors and Affiliations

  • Fred G. Kantrowitz
    • 1
    • 2
  • George Munoz
    • 1
    • 2
  • Neal Roberts
    • 1
    • 2
  • Sam Schatten
    • 1
    • 2
  • Steve Stern
    • 1
    • 2
  1. 1.Harvard Medical SchoolBostonUSA
  2. 2.Department of RheumatologyBeth Israel HospitalBostonUSA

Personalised recommendations